The Bull Rankings scorecard — our quality-growth score is 66.3 / 100, built from three pillars scored 0–100: Quality 68, Growth 66, Value 65 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 17% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Xylem’s current price of $107.49 sits on a foundation of solid quality and a forward‑looking growth narrative that our model rates 66.3/100. The strongest pillar, Quality 68, signals solid earnings power. The weakest, Value 65, still sits on the cheap side of peers, though the cash‑flow math is less forgiving.
Three figures underscore the case: a profit margin of 11.2%, a free‑cash‑flow of $960 m that fuels dividends and buybacks, and a debt‑to‑equity of 0.29 that leaves room for further expansion. Together, they paint a picture of a company that can keep compounding without overleveraging.
What the business actually is
Xylem sells engineered products for water, wastewater, and storm‑water systems. Its Water Infrastructure segment delivers pumps, valves, heat exchangers, and controls that keep municipal and industrial plants running. Applied Water and the treatment businesses offer filtration, disinfection, and biological treatment; its brands include Flygt pumps, Leopold filtration, and Ionpure and Neptune Benson treatment systems. Measurement and Control Solutions provide sensors and controls that optimize water use, while Water Solutions and Services wraps it all in maintenance and support. The customer base ranges from utilities to commercial buildings, and growth comes from utilities upgrading aging water networks, smart metering, and treatment services.
Why it can (or can't) keep compounding
The moat is two‑fold. First, the 11.2% profit margin is solid for a specialty industrial player. Second, the free‑cash‑flow of $960 m is being reinvested through a disciplined buyback program and a dividend hike, both signals that the company is confident its earnings can sustain growth. Competitors cannot replicate Xylem’s integrated product suite—pumps, controls, and treatment systems—without decades of engineering and brand equity. The Buying back stock signal in our model shows management shrinking the share count.
The valuation question
The P/E of 25.6 and PEG of 1.3 look moderate, but the reverse‑DCF is more demanding. At today’s price, the implied free‑cash‑flow growth is ~17% per year (in year one, slowing to 3% a year by year ten). Compare that to the 4.5% revenue growth reported for FY YoY. The gap is wide; the market is already pricing in a dramatic acceleration that the current revenue trajectory does not support. If Xylem can lift revenue growth to the mid‑teens, the stock would be fairly priced; if it stalls, the current price is already too high.
The bear case
The single most damning comparison is the 17% implied growth against 4.5% revenue growth. With a profit margin of 11.2%, a squeeze from commodity costs or weaker utility spending would leave little room for error, eroding free cash flow and blunting buybacks. If margin pressure materializes, the implied 17% growth becomes unrealistic, and the stock could fall sharply.
What would change our mind
- Margin decline below 10% would undermine the quality pillar and invalidate the buyback signal.
- Revenue growth falling below 3% YoY would make the implied 17% growth untenable.
- Debt‑to‑equity rising above 0.5 would constrain future capital deployment and weaken the growth narrative.
If any of these thresholds are breached, the thesis would pivot from a quality‑growth play to a cautious stance.